Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Muscle-Invasive Bladder Carcinoma × Standard of Care × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 53 Neoplasms 49 Prostatic Neoplasms 38 Lung Neoplasms 30 Colorectal Neoplasms 30 Carcinoma, Non-Small-Cell Lung 21 Hematologic Neoplasms 18 Pancreatic Neoplasms 16 Neoplasm Metastasis 14 Head and Neck Neoplasms 14 Urinary Bladder Neoplasms 11 Motor Activity 10 Stomach Neoplasms 9 Squamous Cell Carcinoma of Head and Neck 9 Multiple Myeloma 9 Ovarian Neoplasms 8 Melanoma 8 Anxiety Disorders 8 Triple Negative Breast Neoplasms 7 Hematopoietic and Lymphatic System Neoplasm 7 Glioma 7 Colonic Neoplasms 7 Sarcoma 6 Glioblastoma 6 Gastrointestinal Neoplasms 6 Esophageal Neoplasms 6 Carcinoma, Renal Cell 6 Rectal Neoplasms 5 Mouth Neoplasms 5 Lymphoma 5

Interventions

Nivolumab 3 Cisplatin 2 Albumin-Bound Paclitaxel 2 tislelizumab 1 spartalizumab 1 Taxes 1 Standard of Care 1 Radiotherapy 1 Neoadjuvant Therapy 1 Immunotherapy 1 Gemcitabine 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04724928 2025-01-15

EFFORT-MIBC

University Hospital, Ghent

Phase 2 Recruiting

Muscle-Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡